Ikarian Capital, LLC Acadia Pharmaceuticals Inc Transaction History

Ikarian Capital, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$16.32 - $20.92 $4.32 Million - $5.54 Million	-265,000 Reduced 81.54%	60,000 $1.13 Million
Q3 2022 Nov 14, 2022	BUY	$14.11 - $18.27 $4.59 Million - $5.94 Million	325,000 New	325,000 $5.32 Million
Q2 2022 Aug 12, 2022	SELL	$13.01 - $27.22 $24,484 - $51,228	-1,882 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$20.94 - $27.5 $2,449 - $3,217	117 Added 6.63%	1,882 $46,000
Q4 2021 Feb 14, 2022	SELL	$16.79 - $27.09 $4.7 Million - $7.59 Million	-280,000 Reduced 99.37%	1,765 $42,000
Q3 2021 Nov 15, 2021	BUY	$15.78 - $24.77 $1.13 Million - $1.78 Million	71,899 Added 34.26%	281,765 $4.68 Million
Q2 2021 Aug 16, 2021	BUY	$19.4 - $27.42 $3.95 Million - $5.59 Million	203,858 Added 3393.11%	209,866 $5.12 Million
Q1 2021 May 17, 2021	SELL	$25.02 - $54.99 $1.25 Million - $2.75 Million	-50,000 Reduced 89.27%	6,008 $155,000
Q3 2020 Nov 16, 2020	BUY	$36.42 - $57.0 $364,200 - $570,000	10,000 Added 21.74%	56,008 $2.31 Million
Q2 2020 Aug 14, 2020	BUY	$39.26 - $52.73 $1.81 Million - $2.43 Million	46,008 New	46,008 $2.23 Million

279

156M

901K

314K

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.76B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.